Literature DB >> 7363400

Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer.

R D Rubens, R J King, S Sexton, M J Minton, J L Hayward.   

Abstract

Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response to chemotherapy. However, ER+ tumours seem to grow more slowly than ER- ones and the response to chemotherapy tends to be longer in ER+ patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363400     DOI: 10.1007/bf00255457

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Combined cytotoxic and progestogen therapy for advanced breast cancer.

Authors:  R D Rubens; R H Begent; R K Knight; S A Sexton; J L Hayward
Journal:  Cancer       Date:  1978-10       Impact factor: 6.860

2.  The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.

Authors:  M E Lippman; J C Allegra; E B Thompson; R Simon; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  N Engl J Med       Date:  1978-06-01       Impact factor: 91.245

3.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

4.  Some comments on the necessity of receptor determination in human breast cancer.

Authors:  W Jonat; H Maass
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

5.  Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.

Authors:  D T Kiang; D H Frenning; A I Goldman; V F Ascensao; B J Kennedy
Journal:  N Engl J Med       Date:  1978-12-14       Impact factor: 91.245

6.  Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.

Authors:  R D Rubens; R K Knight; J L Hayward
Journal:  Br J Cancer       Date:  1975-12       Impact factor: 7.640

7.  Assessment of response to therapy in advanced breast cancer.

Authors:  J L Hayward; P P Carbone; J C Heusen; S Kumaoka; A Segaloff; R D Rubens
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

8.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  8 in total
  4 in total

1.  Estrogen receptor status of advanced breast cancer immediately before chemotherapy does not predict for response.

Authors:  J F Stewart; J L Hayward; R D Rubens; R J King
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Adjuvant chemotherapy of breast cancer: hope--reality--hazard?

Authors:  H Vorherr
Journal:  Klin Wochenschr       Date:  1984-02-15

3.  The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.

Authors:  I Mitchell; N Deshpande; R Millis; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.

Authors:  B Fisher; C K Redmond; D L Wickerham; H E Rockette; A Brown; J Allegra; D Bowman; D Plotkin; J Wolter
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.